RE:RE:RE:Sirona tweet today The bottle neck is resources, and the plan is to avoid dilution at all costs, which we all can agree on.
They got the top 10 pharma to flip some $$$ into the trial, without diluting our base, thats good.
The moment we get additional cash incoming (deals or non dilutive financing), I think we will all see a big change in the pace of clinical trials, partnerships, deals etc. LIP is the golden egg, this will drive share price up quickly.
On the product, I only wish I had invested in Tesla before they launched their first production vehicle fleet. We are not them, but we need to get this in our heads soon.